Adrenal Cortex Disease disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: ADR009 MIFTS: 40	Adrenal Cortex Disease Categories: Endocrine diseases
Genes Tissues Related diseases Publications Pathways Drugs Expand all tables

Sources

Aliases & Classifications for Adrenal Cortex Disease

MalaCards integrated aliases for Adrenal Cortex Disease:

Name: Adrenal Cortex Disease ¹² ¹⁵

Adrenal Cortex Diseases ⁴⁵ ⁷⁴

Classifications:

MalaCards categories:
Anatomical: Endocrine diseases

See all MalaCards categories (disease lists)

External Ids:

Disease Ontology ¹² DOID:3952

MeSH ⁴⁵ D000303

UMLS ⁷⁴ C0001614

Sources

Summaries for Adrenal Cortex Disease

MalaCards based summary : Adrenal Cortex Disease, also known as adrenal cortex diseases, is related to primary pigmented nodular adrenocortical disease and acute adrenal insufficiency. An important gene associated with Adrenal Cortex Disease is POMC (Proopiomelanocortin), and among its related pathways/superpathways are Aldosterone synthesis and secretion and Corticotropin-releasing hormone signaling pathway. The drugs Mecasermin and Doxorubicin have been mentioned in the context of this disorder. Affiliated tissues include cortex, adrenal cortex and pituitary, and related phenotypes are Increased cell death HMECs cells and behavior/neurological

Wikipedia : ⁷⁷ Situated along the perimeter of the adrenal gland, the adrenal cortex mediates the stress response... more...

Sources

Related Diseases for Adrenal Cortex Disease

Diseases related to Adrenal Cortex Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 104)

#	Related Disease	Score	Top Affiliating Genes
1	primary pigmented nodular adrenocortical disease	32.0	PDE11A POMC PRKAR1A
2	acute adrenal insufficiency	10.4	POMC REN
3	allergic encephalomyelitis	10.4	CRH POMC
4	gangliocytoma	10.4	CRH POMC
5	ovarian serous adenofibroma	10.4	NR3C1 POMC
6	inappropriate adh syndrome	10.4	POMC REN
7	bronchus adenoma	10.4	POMC SST
8	bronchial adenomas/carcinoids childhood	10.4	POMC SST
9	acidophil adenoma	10.4	POMC SST
10	allergic urticaria	10.4	CRH NR3C1
11	aldosterone-producing adenoma	10.4	CYP11B2 KCNJ5
12	hypoaldosteronism	10.4	REN POMC CYP11B2
13	familial glucocorticoid deficiency	10.3	REN POMC NR0B1
14	acth deficiency, isolated	10.3	CRH POMC
15	arthrogryposis, distal, type 3	10.3	NR3C2 REN
16	adrenal cortical adenoma	10.3	CYP11B1 POMC PRKAR1A
17	mental depression	10.3	CRH NR3C1 POMC
18	ectopic cushing syndrome	10.3	CRH POMC SST
19	chronic fatigue syndrome	10.3	CRH NR3C1 POMC
20	hormone producing pituitary cancer	10.3	PRKAR1A SST
21	scleredema adultorum	10.3	INS POMC
22	familial hyperaldosteronism	10.3	KCNJ5 CYP11B2 CYP11B1
23	pseudohypoaldosteronism, type i, autosomal dominant	10.3	NR3C2 REN
24	adenohypophysitis	10.3	POMC PRL
25	familial hypertension	10.2	CYP11B2 NR3C2 REN
26	pseudohyperkalemia, familial, 2, due to red cell leak	10.2	CYP11B2 NR3C2 REN
27	mood disorder	10.2	CRH NR3C1 POMC
28	steroid inherited metabolic disorder	10.2	CYP11B1 CYP11B2 POMC REN
29	male reproductive organ benign neoplasm	10.2	POMC PRKAR1A
30	hypothalamic disease	10.2	POMC CRH PRL
31	hypothyroidism, congenital, nongoitrous, 4	10.2	CRH POMC PRL
32	burns	10.2	CRH INS
33	sella turcica neoplasm	10.2	POMC PRL
34	tuberculum sellae meningioma	10.2	POMC PRL
35	duodenal somatostatinoma	10.2	INS SST
36	amenorrhea	10.2	CRH POMC PRL
37	postgastrectomy syndrome	10.2	INS SST
38	hypoadrenalism	10.2	CRH POMC
39	urinary system disease	10.1	INS POMC REN
40	pituitary infarct	10.1	SST PRL POMC
41	chiasmal syndrome	10.1	SST PRL POMC
42	melancholia	10.1	CRH PRL
43	prolactin producing pituitary tumor	10.1	PRL SST
44	pancreatic endocrine carcinoma	10.1	SST POMC INS
45	adrenal carcinoma	10.1	CRH CYP11B1 CYP11B2 POMC REN
46	tsh producing pituitary tumor	10.1	SST PRL POMC
47	endogenous depression	10.1	CRH INS NR3C1
48	pheochromocytoma	10.1	CRH POMC REN SST
49	functioning pituitary adenoma	10.1	SST PRL POMC
50	hypokalemia	10.1	REN POMC NR3C2 NR3C1

Graphical network of the top 20 diseases related to Adrenal Cortex Disease:

Sources

Symptoms & Phenotypes for Adrenal Cortex Disease

GenomeRNAi Phenotypes related to Adrenal Cortex Disease according to GeneCards Suite gene sharing:

²⁷

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Increased cell death HMECs cells	GR00103-A-0	9.02	INS NR0B1 NR3C1 NR3C2 USP8

MGI Mouse Phenotypes related to Adrenal Cortex Disease:

⁴⁷ (show all 14)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	behavior/neurological	MP:0005386	10.34	AIRE CRH CYP11B1 HSD11B1 INS NR3C1
2	homeostasis/metabolism	MP:0005376	10.34	AIRE ARMC5 CRH CYP11B1 CYP11B2 HSD11B1
3	growth/size/body region	MP:0005378	10.32	AIRE ARMC5 CRH CYP11B1 CYP11B2 HSD11B1
4	endocrine/exocrine gland	MP:0005379	10.27	AIRE ARMC5 CRH CYP11B1 CYP11B2 HSD11B1
5	cardiovascular system	MP:0005385	10.25	CYP11B1 CYP11B2 HSD11B1 INS KCNJ5 NR3C1
6	hematopoietic system	MP:0005397	10.16	AIRE CRH CYP11B2 HSD11B1 INS NR3C1
7	immune system	MP:0005387	10.14	AIRE CRH CYP11B2 HSD11B1 INS NR3C1
8	adipose tissue	MP:0005375	10.08	CRH CYP11B2 HSD11B1 INS NR3C1 POMC
9	liver/biliary system	MP:0005370	10.07	AIRE CRH CYP11B2 HSD11B1 INS NR3C1
10	mortality/aging	MP:0010768	10.06	AIRE ARMC5 CYP11B1 INS NR3C1 NR3C2
11	nervous system	MP:0003631	9.93	AIRE CRH CYP11B2 HSD11B1 INS NR3C1
12	muscle	MP:0005369	9.8	CYP11B1 HSD11B1 INS NR3C1 NR3C2 PRKAR1A
13	renal/urinary system	MP:0005367	9.56	CRH CYP11B1 CYP11B2 INS NR3C1 NR3C2
14	reproductive system	MP:0005389	9.23	AIRE CYP11B2 INS NR0B1 NR3C1 PRKAR1A

Sources

Drugs & Therapeutics for Adrenal Cortex Disease

Drugs for Adrenal Cortex Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 162)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Mecasermin

Approved, Investigational

Phase 3

68562-41-4

Doxorubicin

Approved, Investigational

Phase 3,Phase 2,Phase 1

23214-92-8

31703

Etoposide

Approved

Phase 3,Phase 2

33419-42-0

36462

Lenograstim

Approved, Investigational

Phase 3

135968-09-1

Cisplatin

Approved

Phase 3,Phase 2,Phase 1

15663-27-1

2767 441203 84093

Mitotane

Approved

Phase 3,Phase 2

53-19-0

4211

Streptozocin

Approved, Investigational

Phase 3

18883-66-4

29327

Doxil

Approved June 1999

Phase 3,Phase 2,Phase 1

31703

Antineoplastic Agents, Hormonal

Phase 3,Phase 2

Antineoplastic Agents, Phytogenic

Phase 3,Phase 2,Phase 1

Antimitotic Agents

Phase 3,Phase 2,Phase 1

insulin

Phase 3,Phase 2

Insulin, Globin Zinc

Phase 3,Phase 2

Mitogens

Phase 3,Phase 2

Etoposide phosphate

Phase 3,Phase 2

Anti-Bacterial Agents

Phase 3,Phase 2,Phase 1,Not Applicable

Antibiotics, Antitubercular

Phase 3,Phase 2,Phase 1

Immunologic Factors

Phase 3,Phase 2,Phase 1

Topoisomerase Inhibitors

Phase 3,Phase 2,Phase 1

Adjuvants, Immunologic

Phase 3,Phase 2,Phase 1

Keratolytic Agents

Phase 3

Podophyllotoxin

Phase 3

518-28-5

Dermatologic Agents

Phase 3

Paclitaxel

Approved, Vet_approved

Phase 2,Phase 1

33069-62-4

36314

Sorafenib

Approved, Investigational

Phase 2

284461-73-0

216239 406563

Epinephrine

Approved, Vet_approved

Phase 2,Phase 1,Not Applicable

51-43-4

5816

Racepinephrine

Approved

Phase 2,Phase 1,Not Applicable

329-65-7

838

Dexamethasone acetate

Approved, Investigational, Vet_approved

Phase 2,Phase 1

1177-87-3

Dexamethasone

Approved, Investigational, Vet_approved

Phase 2,Phase 1

50-02-2

5743

Hydrocortisone

Approved, Vet_approved

Phase 2,Phase 1,Not Applicable

50-23-7

5754

Hydrocortisone acetate

Approved, Vet_approved

Phase 2,Phase 1,Not Applicable

50-03-3

Axitinib

Approved, Investigational

Phase 2

319460-85-0

6450551

acetic acid

Approved

Phase 2

64-19-7

176

Etomidate

Approved

Phase 1, Phase 2

33125-97-2

667484 36339

Sunitinib

Approved, Investigational

Phase 2

557795-19-4, 341031-54-7

5329102

Vincristine

Approved, Investigational

Phase 2

2068-78-2, 57-22-7

5978

Docetaxel

Approved, Investigational

Phase 2

114977-28-5

148124

Gefitinib

Approved, Investigational

Phase 2

184475-35-2

123631

Oxaliplatin

Approved, Investigational

Phase 2

61825-94-3

43805 6857599 5310940 9887054

Sodium Citrate

Approved, Investigational

Phase 2

68-04-2

Tamoxifen

Approved

Phase 2

10540-29-1

2733526

nivolumab

Approved

Phase 2,Phase 1

946414-94-4

Ipilimumab

Approved

Phase 2

477202-00-9

Pembrolizumab

Approved

Phase 2

1374853-91-4

Vitamin A

Approved, Nutraceutical, Vet_approved

Phase 2

68-26-8, 22737-96-8, 11103-57-4

9904001 445354

Tyrosine

Approved, Investigational, Nutraceutical

Phase 2

60-18-4

6057

Citric Acid

Approved, Nutraceutical, Vet_approved

Phase 2

77-92-9

311

Lactitol

Investigational

Phase 2

585-88-6, 585-86-4

493591

Gossypol

Investigational

Phase 2

303-45-7

Suramin

Investigational

Phase 2,Phase 1

145-63-1

5361

Interventional clinical trials:

(show top 50) (show all 80)

#	Name	Status	NCT ID	Phase	Drugs
1	A Study of OSI-906 in Patients With Locally Advanced or Metastatic Adrenocortical Carcinoma	Completed	NCT00924989	Phase 3	OSI-906
2	Cisplatin-Based Chemotherapy and/or Surgery in Treating Young Patients With Adrenocortical Tumor	Completed	NCT00304070	Phase 3	doxorubicin hydrochloride;cisplatin;mitotane;etoposide
3	Trial in Locally Advanced and Metastatic Adrenocortical Carcinoma Treatment (FIRM-ACT)	Completed	NCT00094497	Phase 3	Etoposide;Doxorubicin;Cisplatin;Streptozotocin;Mitotane
4	Adjuvant Chemotherapy vs. Observation/Mitotane After Primary Surgical Resection of Localized Adrenocortical CarcInoma	Recruiting	NCT03723941	Phase 3	Cisplatin plus Etoposide
5	Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Participants With Stage I-III Adrenocortical Cancer With High Risk of Recurrence (ADIUVO-2)	Recruiting	NCT03583710	Phase 3	Cisplatin;Etoposide;Mitotane
6	Efficacy of Adjuvant Mitotane Treatment (ADIUVO)	Recruiting	NCT00777244	Phase 3	MITOTANE
7	Sorafenib Plus Paclitaxel in Adreno-Cortical-Cancer Patients	Unknown status	NCT00786110	Phase 2	Sorafenib;Paclitaxel
8	Study of Efficacy and Safety of Osilodrostat in Cushing's Syndrome	Completed	NCT02468193	Phase 2	Osilodrostat
9	Medical Safety Follow-up Study for Patients Who Received More Than 28 Days of Total Exposure to BGG492	Completed	NCT02150213	Phase 2	BGG492
10	Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-Pathway in Metastatic, Recurrent or Primary Unresectable Adrenocortical Cancer	Completed	NCT01255137	Phase 2	Axitinib
11	Surgery and Heated Chemotherapy for Adrenocortical Carcinoma	Completed	NCT01833832	Phase 2	Cisplatin;sodium thiosulfate
12	Clinical Trial of Dovitinib in First-line Metastatic or Locally Advanced Non-resectable Adrenocortical Carcinoma	Completed	NCT01514526	Phase 2	Dovitinib
13	A Dose Finding Study of TKM-080301 Infusion in Neuroendocrine Tumors (NET) and Adrenocortical Carcinoma (ACC) Patients	Completed	NCT01262235	Phase 1, Phase 2	TKM-080301
14	Gossypol Acetic Acid in Treating Patients With Recurrent, Metastatic, or Primary Adrenocortical Cancer That Cannot Be Removed By Surgery	Completed	NCT00848016	Phase 2	R-(-)-gossypol acetic acid
15	Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors	Completed	NCT00831844	Phase 2
16	Evaluation of 123I-Iodometomidate for Adrenal Scintigraphy	Completed	NCT00454103	Phase 1, Phase 2	123I-Iodometomidate
17	Sunitinib in Refractory Adrenocortical Carcinoma	Completed	NCT00453895	Phase 2	Sunitinib
18	Surgery Plus Chemotherapy (Doxorubicin, Vincristine and Etoposide), Mitotane, and Tariquidar to Treat Adrenocortical Cancer	Completed	NCT00071058	Phase 2	XR9576 (Tariquidar)
19	Trial With Taxotere and Cisplatin in Non-operable Adrenocortical Carcinoma	Completed	NCT00324012	Phase 2	cisplatin, taxotere
20	Phase II Trial of ZD1839 (Iressa) in Patients With Nonresectable Adrenocortical Carcinoma (ACC)	Completed	NCT00215202	Phase 2	Iressa (ZD1839)
21	Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment	Completed	NCT00091182	Phase 2	oxaliplatin
22	Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors	Completed	NCT00002608	Phase 2	cisplatin;doxorubicin hydrochloride;tamoxifen citrate
23	A Study of Combination Chemotherapy and Surgical Resection in the Treatment of Adrenocortical Carcinoma: Continuous Infusion Doxorubicin, Vincristine and Etoposide With Daily Mitotane Before and After Surgical Resection	Completed	NCT00001339	Phase 2	doxorubicin, vincristine, and etoposide with mitotane
24	Cabozantinib in Treating Patients With Locally Advanced or Metastatic Unresectable Adrenocortical Carcinoma	Recruiting	NCT03370718	Phase 2	Cabozantinib
25	Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors	Recruiting	NCT03333616	Phase 2	Ipilimumab;Nivolumab
26	Cabazitaxel Activity in Patients With Advanced AdrenoCortical-Carcinoma Progressing After Previous Chemotherapy Lines	Recruiting	NCT03257891	Phase 2	Cabazitaxel
27	Surgery and Heated Intraperitoneal Chemotherapy for Adrenocortical Carcinoma	Recruiting	NCT03127774	Phase 2	Cisplatin;Sodium thiosulfate
28	Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors	Recruiting	NCT02867592	Phase 2	Cabozantinib;Cabozantinib S-malate
29	Nivolumab and Ipilimumab in Treating Patients With Rare Tumors	Recruiting	NCT02834013	Phase 2
30	Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic	Recruiting	NCT02721732	Phase 2
31	Activity of Abiraterone Acetate in the Management of Cushing's Syndrome in Patients With Adrenocortical Carcinoma	Active, not recruiting	NCT03145285	Phase 2	Abiraterone Acetate
32	Single Agent Pembrolizumab in Subjects With Advanced Adrenocortical Carcinoma	Active, not recruiting	NCT02673333	Phase 2	Pembrolizumab
33	Cabozantinib in Advanced Adrenocortical Carcinoma	Not yet recruiting	NCT03612232	Phase 2	Cabozantinib-s-malate
34	Nivolumab in Treating Patients With Metastatic Adrenocortical Cancer	Terminated	NCT02720484	Phase 2	Nivolumab
35	IMC-A12 With Mitotane vs Mitotane Alone in Recurrent, Metastatic, or Primary ACC That Cannot Be Removed by Surgery	Terminated	NCT00778817	Phase 2	mitotane
36	S9427, Suramin in Treating Patients With Stage III or Stage IV Adrenocortical Cancer Incurable by Surgery	Terminated	NCT00002921	Phase 2	suramin;therapeutic hydrocortisone
37	Antineoplaston Therapy in Treating Patients With Stage IV Adrenal Gland Cancer	Terminated	NCT00003453	Phase 2	Antineoplaston therapy (Atengenal + Astugenal)
38	Treatment Study Using Bevacizumab for Patients With Adrenocortical Carcinoma	Withdrawn	NCT00469469	Phase 2	Bevacizumab
39	Adrenal Responsiveness During the Perioperative Period in Children Undergoing Congenital Cardiac Surgery	Completed	NCT01839812	Phase 1	Cosyntropin
40	Phase 1 Study of ATR-101 in Subjects With Advanced Adrenocortical Carcinoma	Completed	NCT01898715	Phase 1	ATR-101
41	Seneca Valley Virus-001 and Cyclophosphamide in Treating Young Patients With Relapsed or Refractory Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine Features	Completed	NCT01048892	Phase 1	cyclophosphamide
42	Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Cisplatin for Children With Peritoneal Cancer	Completed	NCT00436657	Phase 1	CHPP of Cisplatin
43	Combination Chemotherapy With Suramin Plus Doxorubicin in Treating Patients With Advanced Solid Tumors	Completed	NCT00003038	Phase 1	doxorubicin hydrochloride;suramin
44	Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu	Completed	NCT00004074	Phase 1
45	A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549	Recruiting	NCT02637531	Phase 1	IPI-549;Nivolumab
46	Possible New Therapy for Advanced Cancer	Terminated	NCT01832974	Phase 1	IL-13-PE
47	Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor	Withdrawn	NCT02831179	Phase 1	Capecitabine;Temozolomide;Veliparib
48	The Effects of Case Management in a Medicaid Managed Care Plan	Unknown status	NCT00385879	Not Applicable
49	Laparoscopic Adrenalectomy Versus Radiofrequency Ablation	Unknown status	NCT02030587	Not Applicable
50	Does Serum-DXM Increase Diagnostic Accuracy of the Overnight DXM Suppression Test in the Work-up of Cushing's Syndrome?	Unknown status	NCT01504555

Search NIH Clinical Center for Adrenal Cortex Disease

Cochrane evidence based reviews: adrenal cortex diseases

Sources

Genetic Tests for Adrenal Cortex Disease

Sources

Anatomical Context for Adrenal Cortex Disease

MalaCards organs/tissues related to Adrenal Cortex Disease:

⁴²

Cortex, Adrenal Cortex, Pituitary, Adrenal Gland, Testes, Liver, Bone

Sources

Publications for Adrenal Cortex Disease

Articles related to Adrenal Cortex Disease:

#	Title	Authors	Year
1	Hypertension and adrenal cortex disease. A review of 100 autopsied cases. ( 5491407 )	Ludwig RN	1970

Sources

Genes for Adrenal Cortex Disease

Genes related to Adrenal Cortex Disease (0 elite genes):

(show all 18)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence
1	POMC	Proopiomelanocortin	Protein Coding	20.68	DISEASES inferred ¹⁵
2	CRH	Corticotropin Releasing Hormone	Protein Coding	19.01	DISEASES inferred ¹⁵
3	REN	Renin	Protein Coding	18.63	DISEASES inferred ¹⁵
4	CYP11B2	Cytochrome P450 Family 11 Subfamily B Member 2	Protein Coding	18.25	DISEASES inferred ¹⁵
5	CYP11B1	Cytochrome P450 Family 11 Subfamily B Member 1	Protein Coding	18.05	DISEASES inferred ¹⁵
6	NR0B1	Nuclear Receptor Subfamily 0 Group B Member 1	Protein Coding	17.94	DISEASES inferred ¹⁵
7	PRKAR1A	Protein Kinase CAMP-Dependent Type I Regulatory Subunit Alpha	Protein Coding	17.67	DISEASES inferred ¹⁵
8	ARMC5	Armadillo Repeat Containing 5	Protein Coding	17.16	DISEASES inferred ¹⁵
9	NR3C1	Nuclear Receptor Subfamily 3 Group C Member 1	Protein Coding	17.14	DISEASES inferred ¹⁵
10	KCNJ5	Potassium Voltage-Gated Channel Subfamily J Member 5	Protein Coding	17.06	DISEASES inferred ¹⁵
11	SST	Somatostatin	Protein Coding	17.04	DISEASES inferred ¹⁵
12	NR3C2	Nuclear Receptor Subfamily 3 Group C Member 2	Protein Coding	16.95	DISEASES inferred ¹⁵
13	PDE11A	Phosphodiesterase 11A	Protein Coding	16.82	DISEASES inferred ¹⁵
14	USP8	Ubiquitin Specific Peptidase 8	Protein Coding	16.8	DISEASES inferred ¹⁵
15	PRL	Prolactin	Protein Coding	16.79	DISEASES inferred ¹⁵
16	AIRE	Autoimmune Regulator	Protein Coding	16.75	DISEASES inferred ¹⁵
17	HSD11B1	Hydroxysteroid 11-Beta Dehydrogenase 1	Protein Coding	16.63	DISEASES inferred ¹⁵
18	INS	Insulin	Protein Coding	16.61	DISEASES inferred ¹⁵

Sources

Variations for Adrenal Cortex Disease

Sources

Expression for Adrenal Cortex Disease

Search GEO for disease gene expression data for Adrenal Cortex Disease.

Sources

Pathways for Adrenal Cortex Disease

Pathways related to Adrenal Cortex Disease according to GeneCards Suite gene sharing:

#	Super pathways	Score	Top Affiliating Genes
1	Aldosterone synthesis and secretion ³⁸ Show member pathways Adrenergic signaling in cardiomyocytes ³⁸ Ca2+ activated K+ channels ⁶⁷ Cortisol synthesis and secretion ³⁸ Cushing syndrome ³⁸ Insulin secretion ³⁸ Melanogenesis ³⁸ Thyroid hormone synthesis ³⁸	12.3	CYP11B1 CYP11B2 INS KCNJ5 NR0B1 POMC
2	Corticotropin-releasing hormone signaling pathway ¹	11.55	CRH CYP11B1 POMC
3	Nuclear Receptor transcription pathway ⁶⁷ Show member pathways Nuclear Receptors ¹	11.5	NR0B1 NR3C1 NR3C2
4	Glucocorticoid receptor regulatory network ¹	11.41	NR3C1 POMC PRL
5	Steroid hormone biosynthesis ³⁸ Show member pathways allopregnanolone biosynthesis ¹	11.25	CYP11B1 CYP11B2 HSD11B1
6	Metabolism of steroid hormones ⁶⁷ Show member pathways Androgen biosynthesis ⁶⁷ Estrogen biosynthesis ⁶⁷ Glucocorticoid andamp; Mineralcorticoid Metabolism ¹ glucocorticoid biosynthesis ¹ Glucocorticoid biosynthesis ⁶⁷ mineralocorticoid biosynthesis ¹ Mineralocorticoid biosynthesis ⁶⁷ Pregnenolone biosynthesis ⁶⁷	10.87	CYP11B1 CYP11B2 HSD11B1 POMC
7	superpathway of steroid hormone biosynthesis ¹ Show member pathways androgen biosynthesis ¹ estradiol biosynthesis I ¹ estradiol biosynthesis II ¹	10.78	CYP11B1 CYP11B2
8	Glucocorticoid Pathway (HPA Axis), Pharmacodynamics ⁶²	10	CRH POMC

Sources

GO Terms for Adrenal Cortex Disease

Cellular components related to Adrenal Cortex Disease according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	endosome lumen	GO:0031904	8.62	INS PRL

Biological processes related to Adrenal Cortex Disease according to GeneCards Suite gene sharing:

(show all 18)

#	Name	GO ID	Score	Top Affiliating Genes
1	glucose homeostasis	GO:0042593	9.73	CYP11B1 INS POMC
2	response to drug	GO:0042493	9.72	CRH REN SST
3	regulation of blood pressure	GO:0008217	9.65	CYP11B1 POMC REN
4	steroid biosynthetic process	GO:0006694	9.63	CYP11B1 CYP11B2 NR0B1
5	adrenal gland development	GO:0030325	9.58	CRH NR0B1
6	cellular response to peptide hormone stimulus	GO:0071375	9.57	CYP11B1 CYP11B2
7	hypothalamus development	GO:0021854	9.54	CRH NR0B1
8	C21-steroid hormone biosynthetic process	GO:0006700	9.52	CYP11B1 CYP11B2
9	cellular response to potassium ion	GO:0035865	9.49	CYP11B1 CYP11B2
10	steroid metabolic process	GO:0008202	9.46	CRH CYP11B1 CYP11B2 HSD11B1
11	hormone-mediated apoptotic signaling pathway	GO:0008628	9.43	CRH SST
12	cellular response to dexamethasone stimulus	GO:0071549	9.43	CRH NR3C1 USP8
13	cellular response to hormone stimulus	GO:0032870	9.4	CYP11B1 CYP11B2
14	aldosterone biosynthetic process	GO:0032342	9.37	CYP11B1 CYP11B2
15	cortisol biosynthetic process	GO:0034651	9.32	CYP11B1 CYP11B2
16	parturition	GO:0007567	9.21	CRH
17	response to immobilization stress	GO:0035902	9.13	CRH NR0B1 REN
18	glucocorticoid biosynthetic process	GO:0006704	8.92	CRH CYP11B1 CYP11B2 HSD11B1

Molecular functions related to Adrenal Cortex Disease according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	steroid hormone receptor activity	GO:0003707	9.5	NR0B1 NR3C1 NR3C2
2	steroid binding	GO:0005496	9.43	HSD11B1 NR3C1 NR3C2
3	3',5'-cyclic-GMP phosphodiesterase activity	GO:0047555	9.4	PDE11A PRKAR1A
4	insulin-like growth factor receptor binding	GO:0005159	9.37	INS REN
5	corticosterone 18-monooxygenase activity	GO:0047783	9.16	CYP11B1 CYP11B2
6	hormone activity	GO:0005179	9.02	CRH INS POMC PRL SST
7	steroid 11-beta-monooxygenase activity	GO:0004507	8.96	CYP11B1 CYP11B2

Sources

Sources for Adrenal Cortex Disease

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ EFO

¹⁸ ExPASy

¹⁹ FDA Approved Drugs

²⁰ FMA

²¹ GeneAnalytics

²² GeneCards

²³ GeneGo (Thomson Reuters)

²⁴ GeneHancer via GeneCards

²⁵ GeneReviews

²⁶ Genetics Home Reference

²⁷ GenomeRNAi

²⁸ GEO DataSets

²⁹ GO

³⁰ GTR

³¹ HGMD

³² HMDB

³³ HPO

³⁴ ICD10

³⁵ ICD10 via Orphanet

³⁶ ICD9CM

³⁷ IUPHAR

³⁸ KEGG

³⁹ LifeMap

⁴⁰ LncRNADisease

⁴¹ LOVD

⁴² MalaCards

⁴³ MedGen

⁴⁴ MedlinePlus

⁴⁵ MeSH

⁴⁶ MESH via Orphanet

⁴⁷ MGI

⁴⁸ miR2Disease

⁴⁹ NCBI Bookshelf

⁵⁰ NCI

⁵¹ NCIt

⁵² NDF-RT

⁵³ NIH Clinical Center

⁵⁴ NIH Rare Diseases

⁵⁵ NINDS

⁵⁶ Novoseek

⁵⁷ Novus Biologicals

⁵⁸ OMIM

⁵⁹ OMIM via Orphanet

⁶⁰ Orphanet

⁶¹ PathCards

⁶² PharmGKB

⁶³ PubMed

⁶⁴ PubMed Health

⁶⁵ QIAGEN

⁶⁶ R&D Systems

⁶⁷ Reactome

⁶⁸ Sino Biological

⁶⁹ SNOMED-CT

⁷⁰ SNOMED-CT via HPO

⁷¹ SNOMED-CT via Orphanet

⁷² TGDB

⁷³ Tocris

⁷⁴ UMLS

⁷⁵ UMLS via Orphanet

⁷⁶ UniProtKB/Swiss-Prot

⁷⁷ Wikipedia